Harnessing ferroptosis for precision oncology: challenges and prospects

被引:0
|
作者
Fernandez-Acosta, Roberto [1 ]
Vintea, Iuliana [1 ,2 ]
Koeken, Ine [1 ]
Hassannia, Behrouz [1 ]
Vanden Berghe, Tom [1 ,3 ,4 ]
机构
[1] Univ Antwerp, Infla Med Ctr Excellence, Dept Biomed Sci, Cell Death Signaling lab, Antwerp, Belgium
[2] Univ Ghent, Dept Math Modelling Stat & Bioinformat, Lab Bioinformat & Computat Genom, BioBix, Ghent, Belgium
[3] VIB UGent Ctr Inflammat Res, Ghent, Belgium
[4] Univ Ghent, Dept Biomed Mol Biol, Ghent, Belgium
关键词
Ferroptosis; Cancer; Machine learning; Liquid biopsy; Cell-free DNA; DNA methylation; Nanopore sequencing; Precision oncology; NONAPOPTOTIC CELL-DEATH; PERSISTER CANCER-CELLS; LIQUID BIOPSIES; IRON ADDICTION; RESISTANCE; IDENTIFICATION; EPIGENETICS; INHIBITOR; VULNERABILITY; PEROXIDATION;
D O I
10.1186/s12915-025-02154-6
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The discovery of diverse molecular mechanisms of regulated cell death has opened new avenues for cancer therapy. Ferroptosis, a unique form of cell death driven by iron-catalyzed peroxidation of membrane phospholipids, holds particular promise for targeting resistant cancer types. This review critically examines current literature on ferroptosis, focusing on its defining features and therapeutic potential. We discuss how molecular profiling of tumors and liquid biopsies can generate extensive multi-omics datasets, which can be leveraged through machine learning-based analytical approaches for patient stratification. Addressing these challenges is essential for advancing the clinical integration of ferroptosis-driven treatments in cancer care.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Harnessing Solute Carrier Transporters for Precision Oncology
    Nyquist, Michael D.
    Prasad, Bhagwat
    Mostaghel, Elahe A.
    MOLECULES, 2017, 22 (04):
  • [2] Harnessing ferroptosis for enhanced sarcoma treatment: mechanisms, progress and prospects
    Jing Zeng
    Xianghong Zhang
    Zhengjun Lin
    Yu Zhang
    Jing Yang
    Pengcheng Dou
    Tang Liu
    Experimental Hematology & Oncology, 13
  • [3] Harnessing ferroptosis for enhanced sarcoma treatment: mechanisms, progress and prospects
    Zeng, Jing
    Zhang, Xianghong
    Lin, Zhengjun
    Zhang, Yu
    Yang, Jing
    Dou, Pengcheng
    Liu, Tang
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2024, 13 (01)
  • [4] Harnessing the potential of reverse-phase protein array technology: Advancing precision oncology strategies
    Masuda, Mari
    Nakagawa, Riko
    Kondo, Tadashi
    CANCER SCIENCE, 2024, 115 (05) : 1378 - 1387
  • [5] Clinician perspectives on communication and implementation challenges in precision oncology
    Hamilton, Jada G.
    Banerjee, Smita C.
    Carlsson, Sigrid, V
    Vera, Jacqueline
    Lynch, Kathleen A.
    Sar-Graycar, Lili
    Martin, Chloe M.
    Parker, Patricia A.
    Hay, Jennifer L.
    PERSONALIZED MEDICINE, 2021, 18 (06) : 559 - 572
  • [6] Realizing the promise of machine learning in precision oncology: expert perspectives on opportunities and challenges
    Nittas, Vasileios
    Ormond, Kelly E.
    Vayena, Effy
    Blasimme, Alessandro
    BMC CANCER, 2025, 25 (01)
  • [7] Challenges of precision oncology for patients and oncologists
    Goerling, Ute
    Rohrmoser, Amy
    Rueter, Gina
    Pichler, Theresia
    Westphalen, C. Benedikt
    Herschbach, Peter
    ONKOLOGE, 2020, 26 (08): : 746 - 751
  • [8] Fluorescent probes for ferroptosis bioimaging: advances, challenges, and prospects
    Yin, Junling
    Zhan, Jingting
    Hu, Qingxia
    Huang, Shuhong
    Lin, Weiying
    CHEMICAL SOCIETY REVIEWS, 2023, 52 (06) : 2011 - 2030
  • [9] Harnessing the evolving CRISPR/Cas9 for precision oncology
    Li, Tianye
    Li, Shuiquan
    Kang, Yue
    Zhou, Jianwei
    Yi, Ming
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [10] Precision oncology in Latin America: current situation, challenges and perspectives
    Calderon-Auaricio, Ali
    Orue, Andrea
    ECANCERMEDICALSCIENCE, 2019, 13